In its 23rd year the World Vaccine Congress Europe is set to be one of our biggest and most exciting events. We will be bringing experts from the whole value chain together in one place for discussion and networking. In attendance this year are some hugely exciting start-ups, who look forward to meeting you. In a previous post we introduced some of these start-ups. We’re pleased to present several more as names continue to come in.
If you are interested in joining the start-ups below, make an application here.
If your application is successful you will receive:
- 1m wall space in the heart of the exhibition as part of our Start-up Zone
- 2 full passes to the conference and exhibition
- Branding and marketing on our event website and other marketing materials
- Access to our networking portal where on site meetings can be arranged with our attendees
To find out who is already signed up, read on!
Market Access Africa:
a healthcare organisation working with public, private, and third sectors to design and deliver transformational healthcare solutions for Africa. It comprises thinkers and doers who are seasoned experts in global healthcare markets, the life sciences, and policy. It brings together relentless passion and decades of experience from living and working on the continent.
a 12-year-old Mexican institution devoted to organising and conducting clinical trials on drugs, vaccines, and medical devices. Over time, and with 100+ studies held, CICA has grown in expertise and skills and currently serves the industry as a Site (CICASITE) and a CRO (CICATRIALS).
Boost Biopharma Inc:
the developer of AdaptVax, a platform that rapidly (<45 days) creates highly immunogenic and expressible protein vaccine antigens. This enables the rapid updating of vaccines to current viral strains. With this technology, Boost has generated a complete library of best-in-class, next-generation SARS-CoV-2 RBD protein antigens that show exceptional results in primate studies conducted in the USA. Furthermore, they are highly expressible, stable, and low cost. The company is led by an experienced team of scientific and business talents.
Allied Pharma Technologies:
specialises in the design and building of full sterile production and development facilities. It offers clients full turnkey solutions from a conceptual design to the installation and commissioning of all required equipment for vaccine production.
One Health Ventures;
an early-stage company developing a proprietary, recombinant, genetic toxoid vaccine against epsilon toxin (ETX). ETX has been implicated in Multiple Sclerosis. OHV seeks a commercial partner(s) to advance the programme into clinic as a novel vaccine for MS in humans.